GSK’s HIV Unit May Cease Operations In Future If HIV Treatments Continue To Be Effective, ViiV Healthcare Chair Says

Bloomberg Business: Success at Glaxo’s HIV Unit May Mean Having to Call It Quits
“HIV drugs are proving to be so effective in containing the virus that GlaxoSmithKline Plc foresees a time, a decade away, when its most profitable business unit may no longer have a purpose. ‘There are diminishing returns in HIV,’ said David Redfern, Glaxo’s chief strategy officer and the chairman of its AIDS treatment unit ViiV Healthcare Ltd. ‘The industry has done a fantastic job of taking the fear of the late ’80s, and the death sentence, and taking that to one tablet a day’…” (Staley, 7/9).